IEV407 / Novartis - LARVOL DELTA

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer (clinicaltrials.gov) - P1 | N=194 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer (clinicaltrials.gov) - P1 | N=194 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals

First-in-human • New P1 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2